PFIZi025-A
B220c16
iPSC line
At European Collection of Authenticated Cell Cultures (ECACC)
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
hPSCreg Name | PFIZi025-A |
Alternative name(s) |
B220c16
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | |
Provider |
|
Depositor | Pfizer Limited - Pfizer (PFIZ) |
Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
External Databases |
|
hPSCreg | PFIZi025-A |
BioSamples | SAMEA104236756 |
ECACC | 66540610 |
Cellosaurus | CVCL_RG02 |
CLO | CLO_0101700 |
Wikidata | Q54947280 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information#
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 25-29 |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
BioSamples | SAMEA104236757 |
hIPSC Derivation#
General |
|
Source cell type |
peripheral blood mononuclear cellA leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
|
Source cell type (free text) | Erythroblast |
Age of donor (at collection) | 25-29 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Genes | |
Is reprogramming vector detectable? |
No |
Methods used |
RT-PCR
|
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
Culture medium | mTeSR™1 |
Passage method | EDTA |
Surface coating | Matrigel / Geltrex |
O2 concentration | 21 |
CO2 concentration | 5 |
Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|||||
SSEA-4 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|||||
SSEA-1 |
No |
Differentiation Potency
In vitro spontaneous differentiation
In vitro spontaneous differentiation
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Sterility |
|
Inoculation for microbiological growth | No Contaminants Detected |
Mycoplasma | Not Detected |
Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
18/20 (46,XX), 1/20 (45,XX,-7), 1/20 (45,XX,-12)
Passage number: 14
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |